Meta-analysis comparing thymosin alpha-1 and interferon-alpha for chronic hepatitis B found similar overall efficacy but thymosin alpha-1 had significantly fewer side effects and better tolerability — supporting its use for patients intolerant of interferon.
Key findingMeta-analysis of thymosin alpha-1 versus interferon-alpha for chronic HBV found similar virological response rates (HBeAg seroconversion) but thymosin
What the researchers found
Meta-analysis of thymosin alpha-1 versus interferon-alpha for chronic HBV found similar virological response rates (HBeAg seroconversion) but thymosin alpha-1 had significantly fewer adverse effects and better tolerability — establishing it as the better-tolerated alternative.
Why it matters
Relevant for thymosin-alpha-1, immune-function, infection.
How the study worked
meta-analysis study.
What this study cannot tell us
See abstract.
How to read the evidence
strong evidence.
When this study was published
Published in 2008.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis.
Antiviral research, 77(2), 136-41
Citation
Yang, Yong-Feng; Zhao, Wei; Zhong, Yan-Dan; Yang, Yi-Jun; Shen, Ling; Zhang, Ning; Huang, Ping. (2008). Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis.. Antiviral research, 77(2), 136-41.